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Abstract 
Background: Fragile X syndrome (FXS) is caused by CGG expansion over 200 repeats at the 5′ UTR of the FMR1 
gene and subsequent DNA methylation of both the expanded sequence and the CpGs of the promoter region. This 
epigenetic change causes transcriptional silencing of the gene. We have previously demonstrated that 5‑aza‑2‑deox‑
ycytidine (5‑azadC) treatment of FXS lymphoblastoid cell lines reactivates the FMR1 gene, concomitant with CpG sites 
demethylation, increased acetylation of histones H3 and H4 and methylation of lysine 4 on histone 3.
Results: In order to check the specificity of the 5‑azadC‑induced DNA demethylation, now we performed bisulphite 
sequencing of the entire methylation boundary upstream the FMR1 promoter region, which is preserved in control 
wild‑type cells. We did not observe any modification of the methylation boundary after treatment. Furthermore, 
methylation analysis by MS‑MLPA of PWS/AS and BWS/SRS loci demonstrated that 5‑azadC treatment has no dem‑
ethylating effect on these regions. Genome‑wide methylation analysis through Infinium 450K (Illumina) showed 
no significant enrichment of specific GO terms in differentially methylated regions after 5‑azadC treatment. We also 
observed that reactivation of FMR1 transcription lasts up to a month after a 7‑day treatment and that maximum levels 
of transcription are reached at 10–15 days after last administration of 5‑azadC.
Conclusions: Taken together, these data demonstrate that the demethylating effect of 5‑azadC on genomic DNA is 
not random, but rather restricted to specific regions, if not exclusively to the FMR1 promoter. Moreover, we showed 
that 5‑azadC has a long‑lasting reactivating effect on the mutant FMR1 gene.
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Background
Fragile X syndrome (FXS; OMIM #300624), the most 
common cause of inherited intellectual disability, is 
caused by the absence of FMRP (fragile X mental retar-
dation protein). This loss of function mutation causes 
dendritic spine dysgenesis [1]. FXS is almost invari-
ably due to a dynamic mutation, i.e. a large expansion 
(full mutation, FM) of an unstable CGG repeat in the 
5′-untranslated region (5′-UTR) of the FMR1 gene. The 
CGG expansion is followed by DNA methylation of the 
5′-UTR of the gene, which causes FMR1 transcriptional 
inactivation and absence of the FMRP protein [2–4]. 
Despite the knowledge of the epigenetic characteristics 
of the expanded FMR1 gene, the molecular mechanisms 
underlying its silencing are not currently known in 
detail. The DNA methylation likely represents the main 
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epigenetic mark that switches off the expanded gene. 
The existence of rare individuals of normal intelligence 
carriers of unmethylated full mutation (UFM) supports 
both the crucial role of DNA methylation in silencing the 
expanded FMR1 gene and the possibility of transcrip-
tion of an expanded allele (over 200 CGGs) [5]. Cell lines 
derived from these individuals might reflect the status of 
FXS cells before epigenetic silencing, which is thought 
to occur at about 11 weeks of gestation [6]. Indeed, the 
epigenetic characterization of their FMR1 locus showed 
histone H3 and H4 hyperacetylation, lysine 4 of histone 
3 (H3K4) methylation, lysine 9 of histone 3 (H3K9) hypo-
methylation, lysine 27 of histone 3 (H3K27) dimethyla-
tion and lack of DNA methylation [7, 8]. This epigenetic 
status is compatible with an euchromatic conforma-
tion of the FMR1 locus, allowing transcription. A simi-
lar epigenetic status can be induced by treatment of FXS 
cells with the DNA demethylating agent 5-aza-2-deoxy-
cytidine (5-azadC), which also causes histone changes 
(H3 and H4 hyperacetylation, H3K4 methylation) that 
actually precede DNA demethylation [9–11]. In accord-
ance with these results, silencing of FMR1 in human 
embryonic stem cells seems to begin from histone modi-
fications prior to DNA methylation [12]. Urbach and col-
leagues showed that FMR1 locus in induced pluripotent 
stem (iPS) cells derived from FXS individuals is hyper-
methylated, thus suggesting that its methylation, once 
established, is stable and not revertible through repro-
gramming techniques [13]. Recently, iPS cells derived 
from fibroblasts of an UFM individual were found to 
be methylated after reprogramming, possibly as conse-
quence of in vitro manipulation [14]. The DNA methyla-
tion is not widespread, but localized only at the FMR1 
locus in FXS lymphocytes and iPS cells [15]. Naumann 
et  al. demonstrated the presence of a DNA methylation 
boundary, 650–800 nucleotides upstream of the CGG 
repeat [16]. This boundary separates, in normal cells, a 
hypermethylated upstream region from the unmethyl-
ated FMR1 promoter, protecting it from the spreading of 
DNA methylation and apparently lost in FXS individu-
als, but not in UFM cell lines [17, 18]. The methylation 
boundary is thought to have a role in chromatin remod-
elling of the FMR1 locus by recruiting a number of pro-
teins [16], such as CTCF (CCCTC-binding factor), the 
first insulator protein found in mammals [19]. Its role 
in regulating the FMR1 gene expression was recently 
defined, suggesting a complex mechanism via chromatin 
loop formation [17]. CTCF does not bind to methylated 
FM alleles, and binding is not restored by pharmaco-
logical demethylation with 5-azadC. This result might be 
explained by failure of drug-induced DNA demethyla-
tion to reverse all modifications that occur during gene 
silencing. As observed on MLH1 and p16 gene, 5-azadC 
treatment did not completely restore normal histone 
code and post-translational modifications of DNA bind-
ing proteins to reestablish long-term expression [20, 21]. 
We previously observed that transcriptionally reactivated 
FXS cell lines restored epigenetic changes consistent with 
an euchromatic status, without fully reaching the euchro-
matic configuration typical of normal control cell lines 
[11]. We demonstrated that 5-azadC-induced demethyla-
tion is partial and transient. After 4 weeks from 5-azadC 
withdrawal, the FMR1 promoter resumed its methylated 
status [10]. We also showed that inhibitors of histone 
deacetylases potentiate the effect of 5-azadC, without 
allowing a substantial reactivation of the gene [22]. These 
experiments suggest that DNA methylation is dominant 
over histone modifications in determining the transcrip-
tional inactivation of the mutant FMR1 gene. This con-
clusion was confirmed by further experiments, studying 
the modest reactivating effect of valproic acid (VPA), 
which acts as inhibitor of histone deacetylases without 
DNA demethylation [23].
In this report, we describe treatments with 5-azadC of 
WT and FXS lymphoblastoid cell lines to improve our 
knowledge of the molecular mechanisms through which 
this compound induces DNA demethylation and FMR1 
transcriptional reactivation. Specifically, the main aim 
was to evaluate the possible diffusion of demethylation 
effect to other loci, different from FMR1. Additionally, we 
analysed the reactivating effect over an extended period 
of time. Our present findings may have implications for 
the possible use of 5-azadC as a FMR1 reactivating drug 
in vivo.
Results
Duration of the FMR1 reactivating effect of 5‑azadC
This study aims also at clarifying the duration of 5-azadC 
effect by measuring the level of reactivation of FMR1 at 
different time points throughout 1  month after discon-
tinuation of the treatment.
The transcriptional reactivation levels of FMR1 and 
the translational expression of FMRP in 5-azadC-
treated cell lines are illustrated in Fig. 1. Two independ-
ent treatments of FXS1 cell line (around 250 CGGs) 
induced a reactivation of the FMR1 transcriptional 
activity around 30 % with respect to normal control at 
T1, with a maximum level at T2, T3 and T4 followed 
by a progressive decrease (Fig.  1a). Two independ-
ent treatments on FXS2 cell line (around 450 CGGs) 
resulted in a reactivation level slightly lower 20  % at 
T1, with a maximum average reactivation of 40 % at T3, 
compared with the untreated WT. Afterwards, there 
was a decrease in transcript, which became undetecta-
ble at T7 (Fig. 1b). A slight increase in FMR1 gene tran-
scriptional activity was observed in 5-azadC-treated 
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WT1 cells, which persisted until 22–25 days after end-
ing the treatment (Fig. 1c). The same trend of transcrip-
tional activity was observed for WT2 cell line (data not 
shown).
In order to determine whether the newly detected 
transcriptional activity was paralleled by restoration of 
the translation, Western blot analysis was performed 
on protein lysates. We observed a slight restoration of 
the FMRP expression in FXS1 and FXS2 after 7 days of 
5-azadC treatment (T1), while it was no longer detecta-
ble after 29 days (T7) (Fig. 1d). This pattern overlaps with 
that of transcription observed by qRT-PCR. This is the 
first report of a partial FMRP expression in a FXS cell line 
after treatment with 5-azadC through Western blot.
Fig. 1 Transcriptional and translational data after 5‑azadC treatment. The upper panel reports the scheme of 5‑azadC treatment with the relative 
time points. Relative quantification of FMR1‑mRNA by RT‑PCR after two independent treatments (n = 2) with 5‑azadC of FXS1 (a) and FXS2 (b) 
cell lines showed increased FMR1‑mRNA expression at T2–T3, decreasing at T6 and T7. The reactivation pattern in WT1 cell line was substantially 
unmodified after 5‑azadC treatment (c). The transcriptional reactivation levels are expressed in percentage of the untreated WT cell line, arbitrarily 
set at 100 %. Western blot with antibody against FMRP and GAPDH on FXS1 and FXS2 cell extracts showed that after 7‑day treatment with 5‑azadC 
(T1) the expression of FMRP was restored and disappeared after 22 days (T7) from the end of the treatment. After 5‑azadC treatment FMRP levels 
did not reach those of untreated WT
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To study whether the persistent reactivating effect 
induced by 5-azadC is associated with post-translational 
histone modifications at the FMR1 locus, we performed 
chromatin immunoprecipitation (ChIP) assays followed 
by quantification of immunoprecipitated DNA (IP-DNA) 
at different time points. Methylation levels of euchro-
matic (H3K4me2 and H3K27me2) and heterochromatic 
(H3K9me2 and H3K27me3) markers of both untreated 
and treated FXS2 cell line are shown in Fig. 2. The meth-
ylation level of H3K4me2 is significantly increased at 
T1, followed by gradual decrease at T6, both in the pro-
moter and in exon 1 (Fig. 2a, b). The methylation profile 
of dimethylated H3K27 is similar to that of H3K4me2 at 
both time points, except for exon 1 region at T6 which 
persists elevated (Fig. 2c, d). Even if statistically not sig-
nificant (untreated vs treated, p > 0.1), the difference is in 
the expected direction. Overall, both euchromatic mark-
ers show a trend that is concordant with the observed 
transcriptional activity of the gene. The methylation 
levels of H3K9me2 were substantially stable (Fig.  2e, f ). 
The observed differences were not statistically signifi-
cant (p  >  0.1) at both time points and regions. Despite 
the lack of statistical significance, the trimethylation 
level of H3K27 (H3K27me3) in the promoter region was 
in accordance with the transcriptional activity of FMR1, 
being slightly lower at T1 than at T6 in the promoter 
region (Fig. 2g). Unexpectedly, we observed a substantial 
(p < 0.1) opposite trend in exon 1 (Fig. 2h).
Evaluation of the 5‑azadC demethylating effect
The study of genomic DNA methylation after 5-azadC 
treatment was performed by bisulphite sequencing, MS-
MLPA of imprinted loci and whole-genome methylation 
analysis in order to study methylation at different levels, 
for specific loci and genome wide.
Bisulphite sequencing of the methylation boundary
The demethylating effect of 5-azadC on the genomic 
regions including part of the CpG island of the FMR1 
promoter (cytosine 45 through 54) and of the methyla-
tion boundary [16] was assessed through bisulphite DNA 
transformation of treated and untreated WT and FXS cell 
lines. As expected, we observed the presence of the meth-
ylation boundary in the untreated WT1 cell line clones, 
which is lost in the untreated FXS1 cell line (Fig.  3a, b, 
upper panels), as already described by Naumann et  al. 
[16]. After the treatment with 5-azadC, the methylation 
profile of WT1 did not substantially change, despite the 
presence of 3 out of 21 clones unmethylated (Fig. 3a, bot-
tom panel). In the FXS1 cell line, the 5-azadC treatment 
changed radically the methylation profile of this region: 
the promoter region became demethylated, as previously 
demonstrated by Pietrobono et al. [10], while the region 
upstream the methylation boundary was not affected, 
preserving its methylated status (Fig. 3b, bottom panel).
FXS2 behaved essentially in the same way (Additional 
file 1: Figure S1), even though the demethylation effect of 
the 5-azadC treatment was lower than that observed for 
the FXS1 cell line, according to the lower levels of FMR1 
transcriptional reactivation and to the CGG expansion of 
around 450 triplets (Fig. 1b).
MS‑MLPA of imprinted loci
To further evaluate the methylation status of the FMR1 
locus, as well as of imprinted loci at chromosomes 15 
and 11, MS-MLPA was performed in both untreated 
and 5-azadC-treated cell lines, according to the scheme 
reported in Fig.  1 (top panel). In particular, MS-MLPA 
is a semi-quantitative method for methylation profiling, 
which briefly consists in hybridization of loci-specific 
probes to the denatured genomic DNA and then diges-
tion with a methylation-sensitive endonuclease.
The first locus analysed was FMR1 (Additional file  2: 
Table S1). The methylation profile of the untreated and 
treated (T1, T3 and T8) WT1 and WT2 cell lines dem-
onstrated the absence of methylation in exon 1, while the 
other exons retained their methylation status. No sub-
stantial changes were observed in the methylation profile 
after 5-azadC treatment, except for exon 7, which became 
partially demethylated, at least at T1 and T3. The FXS1 
untreated sample had a high methylation level, which was 
reduced by 5-azadC treatment at T1 and T3, both in exon 
1 and exon 7. The methylation level was restored to its 
normal level at T8. FXS2 cell line behaved in the same 
way, even though the level of DNA demethylation in exon 
1 at T1 was less marked.
In order to have a more comprehensive view of the 
effect of 5-azadC on other methylated loci, the PWS/
AS locus on chromosome 15 and the BWS/SRS locus on 
chromosome 11 were analysed by MS-MLPA in WT1, 
(See figure on next page.) 
Fig. 2 ChIP analysis of euchromatic and heterochromatic markers at the FMR1 locus. Quantification of IP‑DNA by real‑time PCR after immuno‑
precipitation with antibodies against euchromatic markers (H3K4me2 and H3K27me2) in the promoter (a, c) and exon 1 (b, d) regions of FMR1, 
respectively, positively correlated with the level of transcriptional reactivation observed by quantitative RT‑PCR. Heterochromatic markers (H3K9me2 
and H3K27me3) in the promoter (e, g) and exon 1 (f, h) regions of FMR1, respectively, proved to be relatively stable after treatment with 5‑azadC 
even though the trend was in accordance with the transcriptional data. These results refer to two separate ChIP assay performed on cells from two 
independent experiments on FXS2 cell line at T1 and T6 (n = 2). The statistical analysis was conducted using the Kruskal–Wallis nonparametric test 
(p < 0.1)
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WT2, FXS1 and FXS2 cell lines. In all cell lines, we did 
not observe any substantial change in the methylation 
profile of either locus after the pharmacological treat-
ment (Tables 1, 2). 
Additionally, to rule out a possible effect of the dem-
ethylating agent on the inactive (methylated) X chromo-
some, we also treated three different female WT cell lines 
(WTA, WTB and WTC) with 5-azadC and subsequently 
analysed the methylation profile of FMR1 by MS-MLPA 
(Table 3). The results of this analysis of the two imprinted 
loci PWS/AS and BWS/SRS are detailed in Additional 
file 3: Table S2 and Additional file 4: Table S3. Once again, 
the pharmacological treatment does not seem to affect 
the methylation levels in any of the analysed regions.
Whole‑genome methylation analysis
In order to investigate the demethylating effect of 5-azadC 
on global DNA, we performed a whole methylation study 
(See figure on previous page.) 
Fig. 3 Bisulphite analysis of the FMR1 methylation boundary after 5‑azadC treatment. A scheme of the methylation boundary in the 5′ UTR of the 
FMR1 locus is reported in the upper part of the figure. Bisulphite sequencing of the methylation boundary including the CpG island of the FMR1 
promoter region before (upper panel) and after treatment (bottom panel) with 5‑azadC for 7 days of WT1 revealed no substantial modification of 
the methylation profile (a), while an almost complete demethylation of the promoter region that does not affect the methylation boundary was 
observed in FXS1 after treatment (b). The methylation boundary is indicated by the arrow
Table 1 MS-MLPA analysis of the imprinted locus Prader–Willi/Angelman (PWS/AS) on chromosome 15 for WT, WT2, FXS1 
and FXS2 before and after treatment with 5-azadC (1 µM) at three different time points (T1, T3 and T8)
Only methylation-sensitive probes are listed
Note that the asterisks indicate that the magnitude of the probe ratio exceed the set of arbitrary border values. The italic values represent levels of methylation lower 
than 30 %, while bold italic values represent those between 30 and 70 %
Probes WT1 UT ratio WT1 T1 ratio WT1 T3 ratio WT1 T8 ratio
15‑021.5 NDN 0.48 0.30≪ 0.25≪ 0.59
15‑022.9 SNRPN 0.56 0.43≪ 0.51 0.48
15‑022.9 SNRPN 0.57 0.35≪ 0.41 0.45
15‑022.9 SNRPN 0.58 0.31 ≪* 0.36 ≪* 0.5
15‑022.9 SNRPN 0.41 0.18 0.3 0.22
15‑023.2 UBE3A Exon 1 0 0 0 0
Probes WT2 UT ratio WT2 T1 ratio WT2 T3 ratio WT2 T8 ratio
15‑021.5 NDN 0.48 0.24≪ 0 0.37
15‑022.9 SNRPN 0.52 0.4 0.47 0.61
15‑022.9 SNRPN 0.52 0.39 0.44 0.55
15‑022.9 SNRPN 0.5 0.36≪ 0.47 0.57
15‑022.9 SNRPN 0.41 0.19≪ 0.26 0.32
15‑023.2 UBE3A exon 1 0 0 0 0
Probes FXS1 UT ratio FXS1 T1 ratio FXS1 T3 ratio FXS1 T8 ratio
15‑021.5 NDN 0.36 0.25≪ 0.28≪ 0.47
15‑022.9 SNRPN 0.53 0.35 0.44 0.54
15‑022.9 SNRPN 0.51 0.3 0.41 0.59
15‑022.9 SNRPN 0.55 0.33< 0.39 0.53
15‑022.9 SNRPN 0.4 0.14≪ 0.15≪ 0.25
15‑023.2 UBE3A exon 1 0.06 0.02 0.04 0.04
Probes FXS2 UT ratio FXS2 T1 ratio FXS2 T3 ratio FXS2 T8 ratio
15‑021.5 NDN 0.48 0.31≪ 0.26≪ 0.48
15‑022.9 SNRPN 0.48 0.37 0.5 0.34
15‑022.9 SNRPN 0.39 0.45 0.48 0.55
15‑022.9 SNRPN 0.2 0.41 0.42 0.43
15‑022.9 SNRPN 0.13 0.26 0.19 0.17
15‑023.2 UBE3A exon 1 0.06 0.14≪ 0 0
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Table 2 MS-MLPA analysis of  the imprinted locus Beckwith–Wiedemann/Silver–Russell (BWS/SRS) on  chromosome 
11 for WT1, WT2, FXS1 and FXS2 before and after treatment with 5-azadC [1 µM] at three different time points (T1, T3 
and T8)
Only methylation-sensitive probes are listed
The italic values represent levels of methylation lower than 30 %, bold italic values represent those between 30 and 70 %, while underlined values represent those 
higher than 70 %
Probes WT1 UT ratio WT1 T1 ratio WT1 T3 ratio WT1 T8 ratio
11‑002.0 H19 0 0 0 0
11‑002.0 H19 0.49 0.24≪ 0.26≪ 0.51
11‑002.0 H19 0.54 0.37≪ 0.41≪ 0.57
11‑002.0 H19 0.49 0.28≪ 0.32≪ 0.55
11‑002.1 IGF2 0 0 0 0
11‑002.7 KCNQOT1 0.53 0.38 0.39 0.57
11‑002.7 KCNQOT1 0.46 0.28≪ 0.33≪ 0.51
11‑002.7 KCNQOT1 0.45 0.33 0.37 0.54
11‑002.7 KCNQOT1 0.41 0.3 0.37 0.58
11‑002.9 CDKN1c 0.17 0.18 0.2 0.15
Probes WT2 UT ratio WT2 T1 ratio WT2 T3 ratio WT2 T8 ratio
11‑002.0 H19 0.23 0 0 0
11‑002.0 H19 0.55 0.26≪ 0.26≪ 0.47
11‑002.0 H19 0.54 0.37≪ 0.35≪ 0.5
11‑002.0 H19 0.52 0.35 0.36 0.51
11‑002.1 IGF2 0 0 0 0
11‑002.7 KCNQOT1 0.48 0.41 0.29≪ 0.59
11‑002.7 KCNQOT1 0.44 0.33≪ 0.22≪ 0.52
11‑002.7 KCNQOT1 0.42 0.34 0.26≪ 0.5
11‑002.7 KCNQOT1 0.42 0.35 0.18≪ 0.56
11‑002.9 CDKN1c 0.13 0.15 0 0.15
Probes FXS1 UT ratio FXS1 T1 ratio FXS1 T3 ratio FXS1 T8 ratio
11‑002.0 H19 0.23 0.05 0.07 0.07
11‑002.0 H19 0.54 0.1≪ 0.09≪ 0.1
11‑002.0 H19 0.62 0.42≪ 0.47< 0.59
11‑002.0 H19 0.59 0.32≪ 0.45 0.49
11‑002.1 IGF2 0.02 0.03 0.02 0.02
11‑002.7 KCNQOT1 0.59 0.42 0.54 0.6
11‑002.7 KCNQOT1 0.59 0.33≪ 0.44 0.54
11‑002.7 KCNQOT1 0.51 0.42 0.53 0.5
11‑002.7 KCNQOT1 0.54 0.36 0.49 0.58
11‑002.9 CDKN1c 0.1 0.13 0.16 0.1
Probes FXS2 UT ratio FXS2 T1 ratio FXS2 T3 ratio FXS2 T8 ratio
11‑002.0 H19 0 0 0.19 0
11‑002.0 H19 0.26 0.22 0.23 0.29
11‑002.0 H19 0.67 0.37≪ 0.42≪ 0.47
11‑002.0 H19 0.71 0.47≪ 0.34≪ 0.77
11‑002.1 IGF2 0.19 0.14 0.11 0.18
11‑002.7 KCNQOT1 0.5 0.34 0.68 0.6
11‑002.7 KCNQOT1 0.4 0.42 0.44 0.42
11‑002.7 KCNQOT1 0.55 0.4 0.74 0.58
11‑002.7 KCNQOT1 0.5 0.47 0.44 0.92
11‑002.9 CDKN1c 0.25 0.28 0.3 0.35
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(methylome) using Infinium Human Methylation 450 
BeadChip array. The methylation degree of each CpG sites 
is defined by the β value and ranges between 0 (not meth-
ylated) and 1 (methylated). Each analysed sample shows 
two major peaks of CpG methylation value, i.e. for β = 0 
and 0.8 < β < 1 (Additional file 5: Figure S2).
In order to exclude an ascertainment bias due to pos-
sible differences in the baseline methylation levels of 
lymphoblastoid cell lines, we compared our data with 
data published by Alisch et  al. [15], who examined 
genomic DNA methylation levels of peripheral blood 
and fibroblast-derived iPS cells of FXS patients using the 
Infinium Human Methylation 450 BeadChip array. The 
statistical analysis was performed using the Pearson cor-
relation coefficient, which gives a value between +1 and 
−1 inclusive, where 1 is total positive correlation, 0 is no 
correlation and −1 is total negative correlation. In our 
case, the coefficient ranged from 0.6 to 0.85, showing a 
high positive correlation between the methylation levels 
of our cell lines (numbered from 1 to 9, as detailed in the 
“Methods” section) and the peripheral blood samples of 
Alisch et al. [15] (Additional file 6: Figure S3).
The clustering analysis of the nine samples shows 
the distance and similarity among different cell lines 
and within different samples of each cell line compared 
with the respective untreated one (Fig.  4a). As shown 
in Fig.  4b, after treatment with 5-azadC it is possible 
to observe changes in the methylation profile of each 
treated sample. However, these modifications are not sta-
tistically significant (p > 0.05).
Significantly enriched Gene Ontology (GO) terms 
were summarized through the GO slim subsets in Fig. 5, 
and a schematic list of differentially methylated regions 
(DMRs) with the number of genes content is reported in 
Table 4. The comparison of the DMRs between untreated 
WT (WT1 and WT2) and FXS1 demonstrated an enrich-
ment for a few specific GO terms (Fig. 5a). The compari-
son between untreated WT (WT1 and WT2) and FXS2 
(Fig. 5b) revealed a discrete enrichment of a few specific 
GO terms. Of note, the analysis of FXS1 and FXS2 cell 
lines showed no DMRs in the comparison between the 
two corresponding treated samples. The complete list of 
DMRs in the two comparisons illustrated in Fig.  5 with 
their chromosome position is reported in Additional 
file 7: Table S4 and Additional file 8: Table S5.
Discussion
Many efforts have been made in terms of possible phar-
macological approaches to FXS, aiming either at mimick-
ing FMRP functions or at restoring the transcriptionally 
active epigenetic profile of FMR1 [24].
In vitro studies directed at restoring FMR1 activity by 
reinstating its active epigenetic profile showed promising 
results [9–11, 23, 25], leading to a couple of pilot clinical 
trials [26, 27].
The major objection to use drugs like 5-azadC or 
HDAC inhibitors is that their action could be unspecific 
and genome wide, with unforeseeable damaging conse-
quences, even though a microarray screening of 10,814 
genes showed that a very limited set of genes are actually 
Table 3 MS-MLPA analysis on the FMR1 locus before and after 7-day treatment with 5-azadC (T1) of three different nor-
mal control female cell lines (WTA, B and C)
Only methylation-sensitive probes are listed
Note that the asterisks indicate that the magnitude of the probe ratio exceeds the set of arbitrary border values. The italic values represent levels of methylation lower 
than 30 %, bold italic values represent those between 30 and 70 %, while underlined values represent those higher than 70 %
Probes WTA UT ratio WTA T1 ratio WT B UT ratio WT B T1 ratio WTC UT ratio WTC T1 ratio
Prom 0.48 0.38 0.52 0.3≪ 0.52 0.37≪
Prom 0.47 0.25 0.42 0.32 0.53 0.25
Exon 1 0.33 0.26 0.27 0.3 0.39 0.28
Intron 1 0.56 0.36 0.52 0.19≪ 0.68 0.42
Intron 1 0.25 0.19 0.3 0.4 0.38 0.23
Intron 1 0.36 0.24 0.35 0.25 0.35 0.25
Intron 1 0.35 0.24 0.3 0.25 0.39 0.26
Exon 7 0.98 0.46 ≪* 0.98 0.6 ≪* 0.93 0.58 ≪*
Exon 17 0.97 0.9 0.94 0.93 0.97 0.88
Exon 1 AFF2 0.52 0.45 0.54 0.43≪ 0.61 0.42≪
Exon 1 AFF2 0.49 0.37 0.42 0.33 0.42 0.33
Exon 1 AFF2 0.23 0.23 0.3 0.19≪ 0.34 0.24
Exon 1 AFF2 0.46 0.3 0.49 0.36 0.53 0.38
Exon 1 AFF2 0.27 0.17 0.22 0.14 0.38 0.23
Xp22 0.41 0.34 0.38 0 0 0
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Fig. 4 Dendrogram and heat map of the methylation profile in the analysed samples. Dendrogram of the nine samples demonstrates a cluster‑
ing of samples 4–6 (FXS1 UT and the two different 5‑azadC treatments, respectively) and 7–9 (FXS2 UT and the two different 5‑azadC treatments, 
respectively), as expected (a). The distance between sample 1 (WT2 UT) and samples 2 and 3 (WT1 UT and WT1 T1, respectively) and the similar‑
ity between samples 2 and 3 can be explained by intrinsic difference and similarities between different cell lines. The closeness between sample 
1 (WT2 UT) and 4 (FXS1 UT) confirms the observations by Alisch et al. [15]. Heat map of the methylation profile of randomly sampled loci of all 
analysed samples shows that samples from the same cell line type clustered together (b). It is possible to observe some changes in the methylation 
profile after treatment with 5‑azadC that do not reach statistical significance (p > 0.05)
transcriptionally upregulated by treatment with 5-azadC 
(51 genes) and/or with trichostatin A (23 genes) [28].
To shed more light on this debated question, we extended 
our previous studies on the epigenetics of the FMR1 pro-
moter to other genomic regions and eventually to the entire 
genome. Although only H3K4me2 data reached statisti-
cal significance (p < 0.01), the overall picture of ChIP assay 
results showed a consistency of the euchromatic mark-
ers (H3K4me2 and H3K27me2) with the transcriptional 
data, while the heterochromatic markers (H3K9me and 
H3K27me3) did not change substantially during the tran-
sition of the FMR1 gene from transcriptionally inactive to 
transcriptionally active. These last data confirm and extend 
previous findings, which showed that the methylation level 
of H3K9me2 is not substantially affected by treatment with 
5-azadC and that, in UFM cell lines, the epigenetic profile of 
this marker was more similar to that of the FXS cells [11, 23].
To complete the evaluation of the epigenetic effects of 
5-azadC, as well as concerns about its lack of specificity, 
we used three different approaches to investigating the 
changes in DNA methylation at different levels: (1) site 
specific (bisulphite sequencing); (2) locus specific (MS-
MLPA); (3) global (whole methylation analysis).
The bisulphite sequencing analysis of the methylation 
boundary [16] and of the promoter region of FMR1 dis-
closed that while the promoter region of FXS cells under-
went a substantial demethylation, as already observed 
[10], the methylation boundary was not affected by 
treatment with 5-azadC. This new finding suggests 
that 5-azadC does not act indiscriminately throughout 
genomic DNA and that constitutively methylated regions 
are somehow “protected” from its demethylating effect. 
To confirm the validity of this concept, we checked the 
methylation status of other genomic sites, specifically the 
two well-known imprinted loci PWS/AS and BWS/SRS, 
through MS-MLPA. The methylation profile of both loci 
remained substantially unchanged after 5-azadC treat-
ment. MS-MLPA analysis of the FMR1 locus and of the 
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two imprinted loci analysed in three different WT female 
cell lines did not show any significant modification after 
the demethylating treatment. On the whole, these data 
strengthen the assumption that some genomic regions 
are indeed shielded from the demethylating action of 
5-azadC. Finally, the whole methylation analysis showed 
that the methylation changes induced by 5-azadC did not 
affect significantly DMRs. A broad distribution of sev-
eral GO terms or a discrete distribution of few of them 
was observed (Fig.  5; Table  4). More importantly, we 
observed a very strong positive correlation (p < 0.000001) 
between the methylation profiles of lymphoblastoid cell 
lines employed in this study and that of a set of different 
peripheral blood samples (and iPS cell lines) described by 
Alisch et al. [15]. These data argue against the possibility 
that the lack of methylation changes after treatment with 
5-azadC may be interpreted as due to a different pattern 
of DNA methylation in lymphoblastoid cell lines, com-
pared with peripheral blood cells. In fact, different com-
parative genome-wide DNA methylation studies between 
lymphocytes and their derived lymphoblasts demon-
strated differences in methylation profile of both cell 
line types. The direction of these changes in DNA meth-
ylation was often not consistent, i.e. hypermethylation of 
some regions and hypomethylation of others in lympho-
blasts with respect to lymphocytes. These DMRs seemed 
to reflect differences in methylation between B lympho-
cytes and other subtypes of white blood cells, considering 
the monoclonal nature of lymphoblasts and their modi-
fications throughout virus transformation and culturing 
procedure [29–31]. Nevertheless, another study showed 
a high correlation between lymphocytes and virus-trans-
formed lymphoblasts from the same donor in terms of 
DNA methylation and transcription pattern [32]. In any 
case, the strong correlation we observed between lymph-
oblastoid cell lines and peripheral blood cells supports 
the consistency and validity of our results.
To date, 5-azadC is the only compound known to 
induce a good transcriptional activity of the expanded 
and silenced FMR1 gene. Previous experiments with 
5-azadC investigated the transcriptional activity of FMR1 
after 7 days of administration, when the levels of FMR1 
mRNA increased to 30–40  % of a WT cell line, and 
again at 30 days after the last dose administration, when 
complete absence of transcriptional activity, due to the 
Fig. 5 Comparison between samples with respect to GO terms. In a is reported the comparison between WT1 and WT2 versus untreated FXS1. 
Note the enrichment of DMRs for only three GO terms. There is a broad distribution of DMRs over several GO terms in the comparison between 
WT1 and WT2 versus FXS2, although it is possible to identify two major enriched ones (anatomical structure development and cellular nitrogen 
compound metabolic process) (b)
Table 4 List of  differentially methylated sites (DMS), dif-
ferentially methylated regions (DMRs) and  genes content 
in the four comparisons
Comparison DMS DMR Genes
WT1 and WT2 versus FXS1 7343 40 32
WT1 and WT2 versus FXS2 33,950 365 300
FXS1 UT versus FXS1 T1 (n = 2) 1706 0 0
FXS2 UT versus FXS2 T1 (n = 2) 528 0 0
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remethylation of the CpG island of the promoter region, 
was observed [10]. Now we have investigated the changes 
in FMR1 transcription level occurring between day 1 and 
day 30 after cessation of the treatment, in order to meas-
ure its effective duration. Both FXS cell lines showed 
the expected transcriptional reactivation that, interest-
ingly, persisted for about 10–15  days after the last dose 
of 5-azadC. The WT cell line did not show any significant 
changes in FMR1 transcriptional level after treatment. 
These results suggest that the effect of 5-azadC on FMR1 
transcription is only temporary, but relatively long-last-
ing, requiring only pulsed administrations, in order to 
keep reactivation of FMR1 in a steady state. One clear 
implication of this finding is the containment of possible 
damaging side effects of 5-azadC.
The administration of 5-azadC to FXS patients has not 
been tried so far. An obvious concern that arises when 
considering the clinical use of 5-azadC is its toxicity. In 
fact, while 5-azacytidine (5-azaC) and 5-azadC are gen-
erally well tolerated in haematological malignancies [33], 
the effects of a long-term treatment on patients affected 
by genetic disorders are unknown. The results presented 
here suggest that use of 5-azadC in a hypothetical trial 
to treat FXS may not require daily administrations of the 
drug, thus limiting its possible undesirable side effects. 
The idea of treating a genetic disease with a demethylat-
ing drug is not new. Besides haematological malignan-
cies, 5-azadC has been used to treat patients with severe 
refractory β-thalassemias, with a reexpression of foetal 
haemoglobin [34]. Moreover, few in vitro treatments with 
5-azadC of genetic syndromes have been reported. Yao 
et al. [35] have treated with 5-azadC three primary human 
BWS cell lines, two β2SP negative and one β2SP positive. 
The non-pleckstrin homology domain β-spectrin (β2SP) 
functions as a potent TGF-β signalling member adaptor 
and is epigenetically silenced by DNA methylation of its 
CpG island in many individuals with BWS without loss 
of imprinting at the IGF2 locus. Treatment with 5-azadC 
caused the reactivation of the β2SP expression in two neg-
ative BWS cell lines correlating with a decrease in DNA 
methylation in both β2SP alleles [35].
A second obstacle to the therapeutic approach with 
5-azadC is the apparent requirement of cell division in 
order for the treatment to be effective. Interestingly, at 
least two reports suggest that 5-azadC may require mini-
mal or no incorporation into DNA to effectively reduce 
the activity of the maintenance DNA methyltransferase 
DNMT1 [36, 37]. Furthermore, Bar-Nur et  al. [38] 
treated FXS-iPS cells and their derived neurons with 
5-azaC and observed a robust FMR1 reactivation after 
treatment. Although it was a pilot study, these authors 
demonstrated that an epigenetic intervention in stable 
nervous cells is possible.
Conclusions
We show for the first time that 5-azadC seems to have a 
discreet level of specificity, with a long-lasting effect. In 
our view, these results call for future studies on FXS-iPS 
cells and their derived neurons, which we consider an 
obligate pre-clinical passage before 5-azadC can be tested 
in a clinical trial.
Methods
Cell lines and treatments
Lymphoblastoid cell lines were established through 
Epstein–Barr virus (EBV) immortalization of peripheral 
blood lymphocytes of two FXS individuals, two normal 
control males (WT) and three normal control females. 
Peripheral blood lymphocytes were obtained after a 
signed informed consent of each participant (or parents 
in the case of FXS patients). Ethics Committee at the 
Catholic University of Rome approved this study (prot. 
N. 9917/15 and prot.cm 10/15). All cell lines had been 
anonymously established in the Institute of Genomic 
Medicine at the Catholic University (Rome) and are 
referred to as follows:
  • FXS1, fragile X syndrome cell line 1, around 250 
CGG repeats;
  • FXS2, fragile X syndrome cell line 2, around 450 
CGG repeats;
  • WT1, wild-type cell line 1, normal control male;
  • WT2, wild-type cell line 2, normal control male;
  • WT A, wild-type cell line A, normal control female;
  • WT B, wild-type cell line B, normal control female;
  • WT C, wild-type cell line C, normal control female.
Cell cultures were grown in RPMI1640 medium 
(Sigma-Aldrich), supplemented with 10  % foetal bovine 
serum (FBS), 2.5  % penicillin/streptomycin and 2.5  % 
l-glutamine at 37 °C with 5 % CO2.
Prior to pharmacological treatment, cell viability was 
assessed through propidium iodide staining (Nucle-
oCounter, Sartorius-Stedim). For each cell culture, we 
seeded 9 × 107 cells/ml in a final volume of 130 ml per 
single flask. 5-AzadC (Sigma-Aldrich, A3656) was added 
to the cell cultures (final concentration 1 µM) for 7 con-
secutive days. The day after the last dose administration, 
an aliquot of the cell suspension was harvested for RNA, 
DNA and protein extraction and for chromatin immuno-
precipitation (ChIP) assays. In order to evaluate the long-
lasting effect of the treatment, the remaining volume was 
subdivided into eight different flasks, and the cultures 
continued according to the scheme reported on the top 
panel of Fig.  1. For each WT cell line, one single treat-
ment was performed, while two independent treatments 
were performed for each FXS cell line (n = 2).
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Quantitative RT‑PCR
Total RNA was extracted by RNeasy mini kit (Qiagen, 
74106). RNA concentration and purity were checked on 
1.5  % agarose gel and by UV spectrophotometer. After-
wards, 500  ng of total RNA was retro-transcribed into 
cDNA by MoMLV-RT (Invitrogen, USA) and 0.6  µg of 
random hexamers (Promega, C118A).
For a relative quantification of each transcript using 
ABI7900HT (Life technologies), the following pre-devel-
oped TaqMan assays were used: FMR1 (Hs00233632_m1) 
and GAPDH (glyceraldehyde-3-phosphate dehydroge-
nase) (Hs02758991_g1), the latter being constitutively 
expressed in every cell and thus used as endogenous 
control. The cycle parameters were: 2  min at 50  °C and 
10 min at 95 °C, followed by 40 cycles with 15 s at 95 °C 
(denaturation) and 1  min at 60  °C (annealing/exten-
sion). The relative quantification of FMR1 transcript 
versus GAPDH transcript was calculated as follows: 2−
[ΔCt(FMR1)−ΔCt(GAPDH)] =  2−ΔΔCt, being ΔCt the difference 
[Ct(FMR1) − Ct(GAPDH)] and Ct the cycle at which the 
detected fluorescence overcomes the threshold.
Western blot
Proteins extracted from untreated and 5-azadC-treated 
FXS1 and FXS2 and WT1 lymphoblasts were resus-
pended in Laemmli buffer, boiled, separated on 8  % 
polyacrylamide gel electrophoresis, transferred to 
Hybond-ECL membrane (GE Healthcare), immu-
nostained and visualized after film exposure using the 
ECL Western blotting kit (GE Healthcare), according to 
the manufacturer. Primary antibodies were used at the 
following concentrations: 1:1000 anti-FMRP mouse poly-
clonal antibody (Immunological Science) and 1:10,000 
anti-GAPDH mouse antibody (Sigma-Aldrich).
Chromatin immunoprecipitation assay and quantification 
of IP‑DNA
To study the histone modifications at the FMR1 locus, 
chromatin immunoprecipitation (ChIP) assay was per-
formed according to the manufacturer (Millipore). His-
tone methylation analysis was performed using two 
different antibodies against dimethyl lysine 9 (H3K9me2, 
Millipore), dimethyl lysine 4 (H3K4me2, Millipore) and 
di- and trimethyl lysine 27 (H3K27me2 and H3K27me3, 
Millipore) on histone 3. In each ChIP assay, antibody 
against rabbit IgG (Thermo Scientific, 1862244) was 
employed and no template control was included. Immu-
noprecipitated DNA (IP-DNA) was extracted by standard 
procedure (phenol/chloroform/isoamilic alcohol 25:24:1) 
and then quantified by real-time PCR (ABI7900HT, Life 
Technologies) using fluorescent probes and primers spe-
cific for both FMR1 and GAPDH, as already published 
[8].
Standard curves for the two FMR1 and for the sin-
gle GAPDH amplicons were constructed with five dif-
ferent DNA dilutions of known concentration [X 
axis =  log(X)] and the corresponding Ct values (Y axis). 
The unknown amount of IP-DNA of FMR1 and GAPDH 
[X axis = log(X)] was calculated from Ct values, through 
the standard curve plot [y = ax + b, that is Ct = ax + b, 
with x = log(X)].
All variables were analysed by means of descriptive sta-
tistics (mean, median, standard deviation and standard 
error of mean). Data were analysed with nonparametric 
statistical Kruskal–Wallis test and with K sample test. 
The level of significance was set at p ≤ 0.01. Data analy-
sis was performed using STATA Intercooled version 9.2 
software (Stata Co.; College Station, Lakeway, TX, USA).
Bisulphite sequencing
Genomic DNA was isolated from treated and untreated 
cells by DNeasy Blood & Tissue kit (Qiagen, 69504). 
The DNA concentration was checked both by absorb-
ance measurements at 260 nm and on agarose gel. Bisul-
phite DNA transformation was performed as previously 
described [17]. Each transformed DNA was amplified 
in seven independent PCR reactions, then pooled and 
recovered from the agarose gel with the StrataPrep DNA 
Gel extraction kit (Stratagene, 400768). The purified PCR 
products were cloned with the StrataClone PCR cloning 
kit (Stratagene, 240205), according to the manufacturer’s 
instructions. After bacterial plating and overnight incu-
bation at 37 °C, white colonies were picked and plasmid 
DNA was extracted. After a pre-screening of the clones 
with PCR using specific plasmid primers (T3 and T7), 
amplification products were sequenced in both direc-
tions with BigDye Terminator version 3.1 Cycle Sequenc-
ing kit (Life Technologies, 4336917) on a 3130 Genetic 
Analyzer (Life Technologies). The modified primers are 
those described by Naumann et al. [16].
MS‑MLPA analysis
Evaluation of DNA methylation through MS-MLPA was 
performed according to the manufacturer protocol (MRC 
Holland). In the MS-MLPA assay, the sequence targeted 
by specific probes contains a restriction site for the HhaI 
endonuclease, able to recognize the unmethylated GCGC 
sequence. Fragment separation was performed through 
capillary electrophoresis (ABI3130 Genetic Analyzer, Life 
Technologies), and the methylation status was established 
through Coffalyser DB software, comparing the signal of 
each probe (that is proportional to the amount of target 
DNA) in each sample after HhaI digestion with the signal 
of the same probe without digestion. At least three ref-
erence samples (untreated WT) were used in all experi-
ments to normalize the data obtained for each test probe 
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of each sample. Based on the methylation status of these 
reference samples, the Coffalyser DB software automati-
cally determines the border allowing for statistical analy-
sis. Reference samples were randomly distributed across 
the plate, to calculate the reproducibility of each probe 
in the reference sample population. No DNA controls 
were included. The genomic regions analysed in the cur-
rent study are: FMR1-AFF2 locus in Xq27.3 (ME029B2), 
Prader–Willi/Angelman syndromes (PWS/AS) locus in 
15q11 (ME028B2) and Beckwith–Wiedemann/Silver–
Russell syndromes (BWS/SRS) locus in 11p15 (ME030C1).
Whole‑genome methylation analysis
Whole methylation study was performed through Infin-
ium Human Methylation 450 BeadChip array in out-ser-
vice (Integragen). This array detects cytosine methylation 
at CpG islands based on highly multiplexed genotyp-
ing of bisulphite-converted genomic DNA. The level of 
methylation for the interrogated locus can be determined 
by calculating the ratio of the fluorescent signals from 
the methylated versus unmethylated sites. The raw data 
are analysed by the proprietary software, and the fluo-
rescence intensity ratios between two bead types are cal-
culated. A ratio value of 0 equals to non-methylation of 
the locus, a ratio of 1 equals to total methylation, a value 
of 0.5 means that one copy is methylated, and the other 
is not, in the diploid human genome (Human Methyla-
tion 450 BeadChip Data Sheet; Illumina website). For the 
present study, nine samples were analysed and numbered 
from 1 to 9, respectively, as follows: untreated WT2, 
untreated WT1 and 7-day treatment of WT1 (WT1 T1), 
untreated FXS1 and two independent 7-day treatments 
(FXS1 T1) (n = 2), untreated FXS2 and two independent 
7-day treatments (FXS2 T1) (n =  2). Differential meth-
ylation was analysed using the minfi package [39]. Data 
were background-corrected and then subject to subset-
quantile within array normalization (SWAN) [40]. Dif-
ferentially methylated positions were identified using the 
minfi F test implementation and selected as those hav-
ing p value < 0.01. Differentially methylated regions were 
identified using the lasso algorithm [41] implemented in 
the ChAMP package [42], by submitting to ChAMP the 
minfi F test output. A threshold of 0.05 was set for the 
adjusted p value. Genes associated with methylation sites 
found in significantly differentially methylated regions, as 
retrieved from the Illumina documentation, were anno-
tated for functional enrichment by accessing the David 
web services [43] through the openpyxl Python library 
(https://openpyxl.readthedocs.org/en/latest/). Signifi-
cantly enriched Gene Ontology terms were summarized 
through the Gene Ontology (GO) slim subsets.
In order to compare our data set from lymphoblastoid 
cell lines with those already published by Alisch et al. [15] 
from lymphocytes and iPS cell lines, we used the Pearson 
correlation coefficient.
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Additional file 1: Figure S1. Bisulphite sequencing of the FMR1 
methylation boundary after 5‑azadC treatment in FXS2 cell line. Partial 
demethylation after treatment with 5‑azadC is limited to the CpG island of 
the promoter region (middle panel), even after 8 days (T1) from 5‑azadC 
withdrawal (bottom panel). The arrow indicates the position of the meth‑
ylation boundary.
Additional file 2: Table S1. MS‑MLPA analysis of the FMR1/AFF2 locus 
before and after 5‑azadC treatment at three different time points (T1, T3 
and T8) of two different normal control cell lines (WT1 and WT2), two 
different treatments of FXS1 and FXS2, respectively. Only methylation‑
sensitive probes are listed.
Additional file 3: Table S2. MS‑MLPA analysis of the PWS/AS locus 
on chromosome 15 before and after 7‑day treatment with 5‑azadC (T1) 
of three different normal control female cell lines (WTA, B and C). Only 
methylation‑sensitive probes are listed.
Additional file 4: Table S3. MS‑MLPA analysis of the BWS/SRS locus 
on chromosome 11 before and after 7‑day treatment with 5‑azadC (T1) 
of three different normal control female cell lines (WTA, B and C). Only 
methylation‑sensitive probes are listed.
Additional file 5: Figure S2. Distribution curve of beta values for each 
of nine different samples. Two main peaks, for beta = 0 and 0.8 < beta < 1, 
are visible; beta = 0 means absence of DNA methylation and beta = 1 
means completely methylated DNA.
Additional file 6: Figure S3. Heat map of the Pearson correlation 
analysis. Heat map illustrating the Pearson correlation coefficient between 
the nine different lymphoblastoid cell lines used for this study (columns 
from 1 to 9) and the data set of peripheral blood and iPS cells published 
by Alisch et al. [2013] (rows). A high correlation has been demonstrated 
with values ranged from 0.6 and 0.85 between our lymphoblastoid cell 
lines and those already published. Statistical significance was reached 
(p < 0.000001).
Additional file 7: Table S4. List of DMRs and their chromosome position 
in the comparison between WT1 and WT2 versus FXS1.
Additional file 8: Table S5. List of DMRs and their chromosome position 
in the comparison between WT1 and WT2 versus FXS2.
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